BRPI0411510A - proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno - Google Patents
proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgenoInfo
- Publication number
- BRPI0411510A BRPI0411510A BRPI0411510-4A BRPI0411510A BRPI0411510A BR PI0411510 A BRPI0411510 A BR PI0411510A BR PI0411510 A BRPI0411510 A BR PI0411510A BR PI0411510 A BRPI0411510 A BR PI0411510A
- Authority
- BR
- Brazil
- Prior art keywords
- expressing cells
- immunizing
- cd11b
- protein
- monoclonal antibody
- Prior art date
Links
- 230000003053 immunization Effects 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 210000002966 serum Anatomy 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000002659 cell therapy Methods 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 abstract 6
- 102100022338 Integrin alpha-M Human genes 0.000 abstract 6
- 241000588807 Bordetella Species 0.000 abstract 2
- 201000005702 Pertussis Diseases 0.000 abstract 2
- 102000030621 adenylate cyclase Human genes 0.000 abstract 2
- 108060000200 adenylate cyclase Proteins 0.000 abstract 2
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 abstract 1
- 208000018150 Bordetella infection Diseases 0.000 abstract 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 abstract 1
- 102100025390 Integrin beta-2 Human genes 0.000 abstract 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
"PROTEìNA, COMPOSIçãO FARMACêUTICA, USO DA PROTEìNA, POLIPEPTìDEO, USO DO MESMO, VETOR, áCIDO NUCLEICO, CéLULA HOSPEDEIRA SORO POLICLONAL ANTICORPO MONOCLONAL, USO DE UM SORO POLICLONAL OU DE UM ANTICORPO MONOCLONAL, MéTODO PARA ALVEJAR IN VITRO UMA MOLéCULA DE INTERESSE COM AS CéLULAS QUE EXPRESSAM CD11B, CéLULAS QUE EXPRESSAM CD11B, PRODUTO DE TERAPIA CELULAR PARA IMUNIZAR UM SER HUMANO OU UM ANIMAL CONTRA UM ANTìGENO, USO DE CéLULAS QUE EXPRESSAM CD11B, E, MéTODO PARA IMUNIZAR UM PACIENTE CONTRA UM ANTìGENO". A invenção diz respeito às toxinas de adenilato ciclase de Bordetella modificadas que são deficientes quanto à ligação de CD11b/CD18 e ao seu uso na preparação de composição farmacêutica para o tratamento da coqueluche e/ou para a proteção contra a infecção por Bordetella. A invenção também diz respeito aos fragmentos específicos de adenilato ciclase de Bordetella que compreendem o domínio de interação CD11b/CD 18 e ao seu uso, especialmente para alvejar uma molécula de interesse com as células que expressam CD11b.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03291486A EP1489092A1 (en) | 2003-06-18 | 2003-06-18 | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
PCT/EP2004/007811 WO2004113372A1 (en) | 2003-06-18 | 2004-06-18 | MODIFIED BORDETELLA ADENYLATE CYCLASE COMPRISING OR LACKING CD11b/CD18 INTERACTION DOMAIN AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411510A true BRPI0411510A (pt) | 2006-07-25 |
Family
ID=33396035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411510-4A BRPI0411510A (pt) | 2003-06-18 | 2004-06-18 | proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno |
Country Status (10)
Country | Link |
---|---|
US (2) | US20060159697A1 (pt) |
EP (2) | EP1489092A1 (pt) |
JP (1) | JP4824550B2 (pt) |
KR (1) | KR20060034645A (pt) |
CN (1) | CN1839152A (pt) |
AU (1) | AU2004249431B2 (pt) |
BR (1) | BRPI0411510A (pt) |
CA (1) | CA2529565A1 (pt) |
RU (1) | RU2421241C2 (pt) |
WO (1) | WO2004113372A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1188446E (pt) | 2000-09-15 | 2009-11-10 | Pasteur Institut | Vectores proteinácios para a distribuição da molécula a células que expressam cd11b |
EP1489092A1 (en) | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
EP1684801B1 (en) * | 2003-11-21 | 2009-12-02 | Institut Pasteur | Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
EP1576967B1 (en) | 2004-03-18 | 2007-09-12 | Institut Pasteur | Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof |
CN101636157A (zh) * | 2007-01-12 | 2010-01-27 | 康乃尔研究基金会有限公司 | 作为抗菌干预的新型靶的腺苷酰环化酶 |
CN101680026A (zh) * | 2007-01-12 | 2010-03-24 | 康乃尔研究基金会有限公司 | 作为真核病原体感染治疗的新型靶的腺苷酰环化酶 |
CA2755694A1 (en) * | 2009-03-23 | 2010-12-02 | Institut Pasteur | Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell |
PT2233569E (pt) | 2009-03-23 | 2014-10-06 | Pasteur Institut | Polipéptidos mutantes de cyaa e derivados de polipéptidos adequados para a entrega de moléculas imunogénicas numa célula |
RU2471868C2 (ru) * | 2010-02-18 | 2013-01-10 | Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) | Мутантная аденилатциклаза, днк, кодирующая ее, бактерия семейства enterobacteriaceae, содержащая указанную днк, и способ получения l-аминокислот |
ES2607059T3 (es) | 2010-09-20 | 2017-03-29 | Wisconsin Alumni Research Foundation | Xenorhabdus, lipopéptido y procedimientos mosquitocidas |
EP2690172A1 (en) | 2012-07-23 | 2014-01-29 | Genticel | CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses |
EP2689786A1 (en) | 2012-07-23 | 2014-01-29 | Genticel | HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders |
WO2016094438A1 (en) * | 2014-12-08 | 2016-06-16 | Board Of Regents, The University Of Texas System | Bordetella adenylate cyclase toxin vaccines and neutralizing antibodies |
JP2018513218A (ja) * | 2015-04-16 | 2018-05-24 | インベントプライズ リミテッド ライアビリティ カンパニー | 百日咳菌免疫原性ワクチン組成物 |
WO2018091613A1 (en) | 2016-11-17 | 2018-05-24 | Ecole Nationale Vétérinaire de Toulouse | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
US20180133301A1 (en) * | 2016-11-17 | 2018-05-17 | École National Vétérinaire de Toulouse (E.N.V.T.) | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
EP3323426A1 (en) | 2016-11-17 | 2018-05-23 | Ecole Nationale Vétérinaire de Toulouse | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
EP3342421A1 (en) | 2016-12-27 | 2018-07-04 | Genticel | Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response |
CN110711205A (zh) * | 2018-07-13 | 2020-01-21 | 北京中台恒基生物技术有限公司 | 一种肿瘤疫苗及其制备方法 |
EP3616717A1 (en) * | 2018-08-31 | 2020-03-04 | Mikrobiologicky ustav AV CR, v.v.i. | Recombinant antigen inducing antibodies for neutralization of bordetella adenylate cyclase toxin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2638169B1 (fr) * | 1988-10-25 | 1991-01-11 | Pasteur Institut | Derives d'adenyl cyclase et leurs utilisations biologiques |
ATE143692T1 (de) * | 1989-11-29 | 1996-10-15 | Smithkline Beecham Biolog | Neuer impfstoff |
DE69334155T2 (de) * | 1992-04-21 | 2008-02-14 | Institut Pasteur | Rekombinante mutanten zur induktion spezifischer immunantworten |
FR2736064B1 (fr) * | 1995-06-30 | 1997-09-05 | Pasteur Institut | Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella |
PT1188446E (pt) * | 2000-09-15 | 2009-11-10 | Pasteur Institut | Vectores proteinácios para a distribuição da molécula a células que expressam cd11b |
EP1489092A1 (en) | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
-
2003
- 2003-06-18 EP EP03291486A patent/EP1489092A1/en not_active Withdrawn
-
2004
- 2004-06-18 CA CA002529565A patent/CA2529565A1/en not_active Abandoned
- 2004-06-18 RU RU2006101326/15A patent/RU2421241C2/ru not_active IP Right Cessation
- 2004-06-18 BR BRPI0411510-4A patent/BRPI0411510A/pt not_active Application Discontinuation
- 2004-06-18 KR KR1020057024407A patent/KR20060034645A/ko not_active Application Discontinuation
- 2004-06-18 CN CNA2004800238103A patent/CN1839152A/zh active Pending
- 2004-06-18 EP EP04741016.2A patent/EP1633776B1/en active Active
- 2004-06-18 JP JP2006516098A patent/JP4824550B2/ja not_active Expired - Fee Related
- 2004-06-18 WO PCT/EP2004/007811 patent/WO2004113372A1/en active Application Filing
- 2004-06-18 AU AU2004249431A patent/AU2004249431B2/en not_active Ceased
-
2005
- 2005-12-16 US US11/304,590 patent/US20060159697A1/en not_active Abandoned
-
2007
- 2007-03-05 US US11/713,708 patent/US7906123B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4824550B2 (ja) | 2011-11-30 |
CA2529565A1 (en) | 2004-12-29 |
AU2004249431B2 (en) | 2009-11-05 |
US7906123B1 (en) | 2011-03-15 |
RU2006101326A (ru) | 2006-07-27 |
JP2007527697A (ja) | 2007-10-04 |
AU2004249431A1 (en) | 2004-12-29 |
RU2421241C2 (ru) | 2011-06-20 |
KR20060034645A (ko) | 2006-04-24 |
EP1489092A1 (en) | 2004-12-22 |
EP1633776B1 (en) | 2017-08-09 |
WO2004113372A1 (en) | 2004-12-29 |
EP1633776A1 (en) | 2006-03-15 |
CN1839152A (zh) | 2006-09-27 |
US20060159697A1 (en) | 2006-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411510A (pt) | proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno | |
Murphy et al. | Five alpha-D-galactopyranosyl-binding isolectins from Bandeiraea simplicifolia seeds. | |
Seymour et al. | A processed multidomain Mycoplasma hyopneumoniae adhesin binds fibronectin, plasminogen, and swine respiratory cilia | |
Prasadarao et al. | A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1 | |
Jolodar et al. | Molecular cloning of an α-enolase from the human filarial parasite Onchocerca volvulus that binds human plasminogen | |
Smith et al. | Protection studies with integral membrane fractions of Haemonchus contortus | |
BRPI0417429A (pt) | anticorpo monoclonal isolado ou uma porção de ligação de antìgeno deste, composição, imunoconjugado, molécula biespecìfica, vetor de expressão, célula hospedeira, camundongo transgênico, hibridoma, e, métodos de inibir uma resposta inflamatória ou autoimune, de tratar uma doença inflamatória ou autoimune, de tratar uma infecção viral ou bacteriana e de preparar um anticorpo anti-ip-10 | |
BR0214137A (pt) | Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos | |
Lu et al. | The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4 | |
JP2021532114A (ja) | 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物 | |
BRPI0412567A (pt) | anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo | |
BRPI0408315A (pt) | anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico | |
JP2003505343A (ja) | ボツリヌス神経毒を含む治療薬 | |
JPH09500867A (ja) | 細胞活性を制御するための新規作用薬 | |
Pfalzgraff et al. | LPS-neutralizing peptides reduce outer membrane vesicle-induced inflammatory responses | |
Winter et al. | The mushroom Marasmius oreades lectin is a blood group type B agglutinin that recognizes the Galα1, 3Gal and Galα1, 3Galβ1, 4GlcNAc porcine xenotransplantation epitopes with high affinity | |
BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
US20100120058A1 (en) | IgE Antibodies to Chimeric or Humanized IgG Therapeutic Monoclonal Antibodies as a Screening Test for Anaphylaxis | |
BR0113915A (pt) | Uso de adenil ciclase da espécie bordetella, composição imunogênica ou farmacêutica, uso da mesma, e , vetor proteináceo | |
Liu et al. | Construction and expression of sTRAIL–melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli | |
WO2017176796A1 (en) | Compositions and methods for preventing and treating disease | |
Bachran et al. | Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way | |
Steeves et al. | Identification of three oligosaccharide binding sites in ricin | |
BR112021016791A2 (pt) | Proteínas de ligação de antígenos que se ligam a bcma | |
Di Girolamo et al. | Evidence that the 50-kDa substrate of brefeldin A-dependent ADP-ribosylation binds GTP and is modulated by the G-protein beta gamma subunit complex. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |